Practical Guide to Address Common Myths in the Pre– and Post–kidney Transplant Management of the Elderly Patient with Cancer: An Opinion Paper Authors: Mary Ann Lim, Naoka Murakami, Christopher D. Blosser, Salma Shaikhouni, Darshana M. Dadhania, Evan T. Hall, Krista Havlin, Arpita Basu Published: 2026 ABSTRACT Two areas of overlap between kidney transplantation and oncology that remain fraught with uncertainty and bias are (1) transplant candidacy for elderly patients with historic or active cancers or premalignant conditions, and (2) managing cancer in elderly kidney transplant recipients. These have led to inadvertent inequities in the care of elderly kidney transplant candidates with historic or active malignancies. Incorporating a patient’s viewpoint and an oncologist’s perspective, we present a nuanced, multidisciplinary approach to management that goes beyond mere consideration of chronological age and focuses on the individual patient and his/her goals. INTRODUCTION As the population ages, the proportion of individuals 70 y or older living with kidney disease is also steadily growing. Kidney transplant (KT) remains the optimal therapy for eligible older adults (older than 70 y ) with advanced or end-stage kidney disease, offering better survival and quality of life than remaining on dialysis while achieving comparable posttransplant outcomes to those seen in younger KT recipients.1 In the past decade we have observed a 2- to 3-fold increase in the number of adult recipients older than 70 y, who have received a KT.2 Chronological age is no longer thought to be a contraindication for KT and transplant centers are increasingly willing to transplant higher risk KT candidates, despite this, disparities in access to transplant among KT recipients 70 y and older have remained.3-5 KT rates consistently lag behind the kidney disease burden observed in older KT candidates,6 with KT rates of only 3.34 per 100 person-years among individuals aged 65–74 y, and 0.5 per 100 person-years among those aged 75 y and older.7 Current guidelines allow transplant centers to weigh patient and clinical characteristics, which amplifies age-related biases. Transplant centers often follow stricter selection guidelines for older patients, given concerns for shorter life expectancy and fear of higher peri- and posttransplant medical/surgical complication rates.3 A study conducted on potentially excellent, older KT candidates with high predicted 3-y survival showed that only 23% of these patients were listed, whereas 8% were transplanted.8 This age-related discrimination is further compounded if the candidates have other age-related comorbidities such as malignancy, cardiovascular disease, or frailty.3 The available transplantation risk-prediction models are ill-suited to accurately guide transplant listing practices in this cohort, as they are population-based and not equipped to assess KT outcomes in older candidates.8 Misperception of the risks and benefits of KT in older adults, combined with the complexity inherent in multimorbidity and organ availability, may result in overly restrictive referral, listing, and transplantation practices in older adults. Malignancy is established as the leading cause of morbidity and mortality in the older population. Cancer risk increases further in those with kidney disease because of immune dysfunction, chronic inflammation, and dialysis vintage.9-11 Elderly candidates with pretransplant malignancy (PTM) have restricted access to waitlisting and KT due to concerns of cancer recurrence in the setting of immunosuppression, cancer-free waittime restrictions, and provider bias and preconceptions about posttransplant outcomes in this cohort.6 In fact, older patients with cancer are less likely to be referred, evaluated, or waitlisted, and those who are waitlisted tend to be younger and healthier than their nonwaitlisted peers with cancer.12 The presence of ≥2 of these comorbidities (eg, PTM, frailty) might be a relative contraindication in a younger KT candidate, but often can result in undue exclusion of many older KT candidates. In this article, we have focused on older KT candidates (70 y or older) with known PTM or premalignant conditions, as these are the leading comorbidities in this cohort, as previously mentioned. This article advocates a more nuanced, objective, and individualized evaluation of older KT candidates with PTM or premalignant conditions, involving a shared and multidisciplinary approach to decision-making. What follows are 10 common preconceptions about older KT candidates/recipients with cancer in the pre- and posttransplant setting. METHODOLOGY A subgroup of the Kidney Pancreas Community of Practice Frailty Work Group convened to identify and address common misconceptions about elderly KT candidates and recipients. The members brainstormed, then voted on the 10 most prevalent misconceptions to be discussed and debunked, using research-backed evidence wherever available and subject-matter expert opinion in areas where evidence is lacking. Myth 1: Transplant and Immunosuppression Will do More Harm Than Good in Elderly Patients With a History of Cancer Assessing risks and benefits of long-term immunosuppression in KT is context-dependent and nuanced, and the statement that transplant and immunosuppression will do more harm than good in elderly patients with a cancer history is an oversimplification. The relative risk of transplantation should be compared with the risk of remaining on dialysis instead of comparing with the general population with a history of cancer (Figure 1).13 The following should be considered when assessing the suitability of each transplant candidate: their cancer history (including cancer type, previous treatment and response), length and status of remission, recurrence risk (including impact of immunosuppression), available therapies in the setting of recurrence (and their possible interaction with immunosuppression and potential impact on allograft function), quality of life gained after KT, and potential for expanding therapeutic options otherwise contraindicated in advanced kidney disease. Because of the complexity of this decision-making, which often involves competing priorities that may evolve with rapidly advancing therapies, we advocate for individualized decision-making in consultation with a multidisciplinary team involving oncologists, transplant nephrologists, referring nephrologists, primary care providers, patients, and their caregivers. Candid discussions among these stakeholders regarding patients’ values and priorities, what they aim to achieve from transplantation, and ensuring patients’ clear understanding of the risks of immunosuppression and cancer recurrence are critical for assessing transplant candidacy. Tables 1 and 2 summarize questions the KT team may ask the oncology team during KT candidacy assessment. One successful example of multidisciplinary care is the Center for Innovations in Cancer and Transplant model at Fred Hutch Cancer Center, where transplant candidates with PTM engage in multidisciplinary assessment and planning with appropriate oncologists and transplant clinicians.13 TABLE 1.Ten questions to ask the oncology team in evaluating a candidate’s transplant suitability1. Please provide a summary of this patient’s cancer history, including previous treatment and response, and length and status of remission (if applicable).2. What is the natural history and expected recurrence risk of this patient’s cancer at this point?3. If recurrence is possible, when is this most likely to happen?4. If recurrence is possible, please comment on available therapeutic strategies, likelihood of success of each strategy, and potential impact on immune system and kidney function (if any).5. What would you estimate the patient’s life expectancy (with/without recurrence)?6. Does this cancer affect the patients’ operative risk?7. What are the recommendations for ongoing surveillance and management for this cancer in the pre-, peri-, and posttransplant periods?8. What infections is this patient at risk of?9. What is the possible impact of immunosuppression on recurrence or progression of this cancer at this point?10.What is the possible impact of immunosuppression on the development of a second cancer? Ten questions to ask the oncology team in evaluating a candidate’s transplant suitability TABLE 2.Questions to ask the oncology team in managing a transplant recipient with cancer1. What would you estimate the patient’s life expectancy (with/without therapy)?2. Does immunosuppression impact cancer progression? (would a reduction in immunosuppression help in cancer remission?)3. What therapies are being considered and please comment on potential impact on immune system and kidney function (if any).4. Are available therapies impacted by the patient’s kidney function?5. What infections is this patient at risk of?6. What short and long-term cardiometabolic and kidney side effects should be considered with these therapies?7. Once in remission, what are the recommendations for ongoing surveillance and management for this cancer? Questions to ask the oncology team in managing a transplant recipient with cancer The relative risk of transplantation in an elderly patient with cancer should be compared with the risk of that same patient remaining on dialysis instead of comparing it to the general elderly population with cancer (Figure adapted from Watschinger et al62). Overall, to maximize the chances of success, the decision to transplant should be accompanied by a commitment to long-term follow-up and surveillance by the patient and the entire multidisciplinary team. Myth 2: Elderly Patients, Especially Those With PTM, Should not Be Listed Because of the Long Waiting Time for Deceased Donor KTs As posttransplant outcomes improve, access to KT has improved for patients with comorbidities who may not have been transplant candidates in the past. Yet, providers often hesitate to list elderly candidates with PTM due to concerns of health deterioration while biding time on the waitlist before a deceased donor becomes available. Clinicians often perceive older KT candidates as being frail and unable to undergo KT, which impacts their timely referral and access to transplant.14 However, perceived frailty is an inadequate proxy for measured frailty even in this vulnerable cohort. Timely, comprehensive evaluation with individualized oncologic risk assessment by providers specializing in oncology and KT can allow for well-informed, safe, and early listing decisions. One might argue that with the organ scarcity, priority should perhaps be given to those with a likelihood of better patient and posttransplant outcomes; however, the ethical principle of utility (maximize use of the kidney in the general population) needs to be balanced with equity (ensuring all candidates have equal and fair access to KT). Living donor transplantation, even from older donors, offers an option to accelerate transplantation.15 Preemptive KT in selected elderly candidates with higher Kidney Donor Profile Index16 or age-matched older deceased donor kidneys has shown better allograft survival when compared with transplant after dialysis initiation.17 Previous studies have shown that old-for-old KT recipients, even from the extremely elderly, whether via single or dual transplantation, had survival benefits over remaining on dialysis in appropriately selected recipients.18-20 A greater proportion of older KT recipients accept extended-criteria donor organs, or kidneys from older donors, resulting in a relative benefit of KT compared with remaining dialysis dependent. Ultimately, the goal should be to improve access to transplants in older adults by appropriately and expeditiously identifying older yet potentially excellent transplantation candidates, even with their age-related comorbid conditions such as PTM. Excluding these candidates from the waitlist based on age, cancer history, or fear of long waiting time perpetuates inequity. Instead, shifting the focus to a shared decision-making model, bolstered by patient-centered metrics, living donor outreach, and expedited alternate deceased donor allocation pathways, will lead to improved and equitable transplant access for the elderly. Myth 3: Frailty Metrics are too Cumbersome to use and Offer no Predictive Value As with other age groups, an appropriately selected elderly KT candidate is likely to have improved survival and quality of life after transplantation. However, assessing frailty in elderly kidney patients is a major challenge due to the provider’s own biases. As a result, often a nonfrail individual is misclassified as frail, which negatively impacts their access to KT.2 Although frailty is a well-established predictor of poor outcomes in both KT and cancer,21,22 in the absence of clear guidelines, frailty assessments remain underused, with only a few centers applying validated tools in KT candidate selection.6,23 Barriers to their widespread use include the number and variety of available frailty assessment metrics, as well as the perception of burdensome time and resources required to use these tools.23 Table 3 provides a summary of available frailty assessment tools that are actionable and help prognosticate for post-KT outcomes. Using these tools, which target different frailty aspects and can be used collectively, can help assess the reversibility of frailty deficits through prehabilitation. TABLE 3.Currently available frailty assessment toolsDomainToolTime needed to performOnline linksFunctional statusKarnofsky Performance Status Scale555–10 min https://www.mdcalc.com/calc/3168/karnofsky-performance-status-scale Eastern Cooperative Oncology Group Performance Status55<1 min https://ecog-acrin.org/resources/ecog-performance-status/ ComorbidityCharlson Comorbidity Index56<1 min https://www.mdcalc.com/calc/3917/charlson-comorbidity-index-cci Frailty assessmentFried Frailty Phenotype Score575 minhttps://efrailty.hsl.harvard.edu/ToolFrailtyPhenotype.html#:~:text=Frailty%20Phenotype%20*%20Administration%20time:%205%20minutes.,physical%20performance%20test.%20*%20Measures%20physical%20frailty.NutritionBody mass index<1 minSerum albuminCognitionMini-Mental State Examination585–10 min https://cgatoolkit.ca/Uploads/ContentDocuments/MMSE.pdf Depression15-Item Geriatric Depression Scale595–7 min https://www.mdcalc.com/calc/10566/geriatric-depression-scale-gds-15 Currently available frailty assessment tools Prehabilitation offers the chance to optimize KT candidates’ overall physical and psychological state through lifestyle modifications, including exercise training, nutritional support, and psychosocial interventions. Mounting evidence shows prehabilitation in waitlist candidates reduces post-KT and chemotherapy toxicity-associated complications while improving candidates’ overall health and quality of life.24 Longitudinal, large cohort studies are needed to better understand and implement prehabilitation programs into pretransplant evaluation practice. Myth 4: Any Immunosuppression has a Negative Impact on all Malignancies Cancers post-KT can be grouped into these potentially overlapping categories: first, cancers prevalent in patients with kidney disease (eg, myeloma, urologic malignancies); second, virally mediated cancers (Table 4)26,27; and finally, cancers dependent on immune surveillance (eg, skin cancer). Cancer post-KT is often associated with increased mortality25 with an overall standardized mortality ratio (SMR) of 2.6.26 Figure 2 shows the standardized incidence rate and SMR of different cancers after transplantation.26,27 Notably, the rate of breast cancer and prostate cancer does not increase after KT, unlike other cancers where the risk is modulated by immunosuppression. TABLE 4.Virally mediated malignancies in KT recipientsCancerAssociation with viral infectionStandardized incidence ratioStandardized mortality ratioReferenceKaposi sarcomaHuman herpes virus 8192.9 (109.9–306.9)5.6 (1.9–12.4) 60 Non-Hodgkin’s lymphomaEpstein-Barr virus,human T-cell lymphotropic virus7.9 (5.8–10.4)5.5 (3.3–8.3) 60 Cervical cancerHuman papilloma virus3.9 (2.6–5.8)2.3 (1.0–4.3) 60 Nasopharyngeal cancerHuman papilloma virus5.4 (3.2–8.5)3.7 (1.4–7.2) 60 Hepatocellular carcinomaHepatitis B virus, hepatitis C virus2.5 (2.0–3.1)1.0 (0.7–1.5) 60 Urothelial carcinomaBK virus 61 KT, kidney transplant. Virally mediated malignancies in KT recipients KT, kidney transplant. Standardized incidence ratio (1992–2003) and standardized mortality ratio (1984–2014) of different cancers after transplantation (data from ANZDATA26,27). NHL, non-hodgkin’s lymphoma. In older adults, the impact of immunosuppression on cancer risk and mortality is less pronounced, likely due to their elevated absolute risk of cancer regardless of transplant status and increased competing mortality risks.28,29 Myth 5: There Is no Concern for Transplantation in Patients With Premalignant Conditions Although few data exist regarding the surveillance and management of premalignant conditions post-KT, experts advocate close long-term follow-up. The diagnosis of premalignant conditions may be more frequent in elderly KT candidates and recipients because of their age but may also result from enhanced surveillance pre- and posttransplant. Table 5 shows select precancerous conditions, and recommended workup and follow-up of each.30-38 TABLE 5.A summary of precancerous conditions and recommended managementCancer potential (compared with general population)Pretransplant workup and managementPosttransplant follow-up (test, frequency, who)Evidence/referenceHPV-associated anogenital lesions (warts, CIN, AIN)Substantially increasedImmunosuppression inhibits the body’s ability to eradicate new HPV infections while allowing HPV replication in latently infected cellsSurgical removal of any lesions will require up-to-date examination before transplantationAnogenital examination + Pap smear±anoscopy/colposcopy and bx; 6–12 mo depending on results and HPV status; colorectal surgeon, gynecologist32,Colon polypsSimilaraSurgical removal of any lesions will require up-to-date examination before transplantationSimilar to general populationa 34,35 MGUSPresumed higher rate malignant transformation but limited long-term data. It is unclear whether immunosuppression affects progressionConsultation with a hematologist and a thorough workup to ensure correct diagnosisCBC, CMP, SPEP, SIF, quantitative immunoglobulins, serum-free light chains, UPEP, UIF; every 6 mo; hematologist 30 Smoldering myelomaPresumed higher rate of malignant transformation but limited long-term data. It is unclear whether immunosuppression affects progressionConsultation with a hematologist and a thorough workup to ensure correct diagnosisCBC, CMP, SPEP, SIF, quantitative immunoglobulins, serum-free light chains, UPEP, UIF; every 6 mo; hematologist 30 IPMNSimilar, risk depends on size and high-risk imaging featuresConsultation with gastroenterologist or pancreatic cyst expert. Depending on size and imaging features, it may need biopsySimilar to general population 36 ACSL of lungNo data but presumed to be highCancer progression believed to be from immune evasionConsultation with pulmonologist. Typically, will warrant a period of radiologic stability±biopsy showing benign findingsChest imaging±biopsy, shorter interval than general population, pulmonologist 37 Thyroid noduleSimilar. No evidence that immunosuppression alters its courseFollow general populationSimilar to general population 38 Monocalonal B-cell lymphocystosisNot clear, limited data show no increase in CLLHematologic evaluation to ensure correct diagnosisClose follow-up with hematologist 30,31 aColorectal cancer risk is higher in lung transplant recipients with cystic fibrosis, liver transplant recipients with primary sclerosing cholangitis and inflammatory bowel disease, and kidney transplant recipients on cyclosporine and azathioprine, but kidney transplant recipients on tacrolimus/mycophenolate mofetil did not have increased risk34; conflicting evidence of risk in patients with polycystic kidney disease.35ACSL, adenocarcinoma spectrum lesion; AIN, anal intraepithelial neoplasia; CBC, complete blood count; CIN, cervical intraepithelial neoplasia; CLL, chronic lymphocytic leukemia; CMP, complete metabolic panel; HPV, human papilloma virus; IPMN, intraductal papillary mucinous neoplasm; IS, immunosuppression; MGUS, monoclonal gammopathy of unclear significance; SIF, serum immunofixation; SPEP, serum protein electrophoresis; UIF, urine immunofixation; UPEP, urine protein electrophoresis. A summary of precancerous conditions and recommended management aColorectal cancer risk is higher in lung transplant recipients with cystic fibrosis, liver transplant recipients with primary sclerosing cholangitis and inflammatory bowel disease, and kidney transplant recipients on cyclosporine and azathioprine, but kidney transplant recipients on tacrolimus/mycophenolate mofetil did not have increased risk34; conflicting evidence of risk in patients with polycystic kidney disease.35 ACSL, adenocarcinoma spectrum lesion; AIN, anal intraepithelial neoplasia; CBC, complete blood count; CIN, cervical intraepithelial neoplasia; CLL, chronic lymphocytic leukemia; CMP, complete metabolic panel; HPV, human papilloma virus; IPMN, intraductal papillary mucinous neoplasm; IS, immunosuppression; MGUS, monoclonal gammopathy of unclear significance; SIF, serum immunofixation; SPEP, serum protein electrophoresis; UIF, urine immunofixation; UPEP, urine protein electrophoresis. Although these conditions do not necessarily preclude transplantation, meticulous pretransplant evaluation and careful long-term posttransplant follow-up are imperative to allow safe transplantation, and early diagnosis and management of malignant transformation should occur. Myth 6: Active Cancer Is an Absolute Contraindication for Transplantation In the past, active cancer was an absolute contraindication for KT, needing a specific cancer-free wait time (based on type, stage, and grade of cancer, and the risk of recurrence) following cancer treatment before being considered for KT. During the last few years, with improved understanding, prognostication, and therapeutic advances of certain cancers, the transplant candidacy for end-stage kidney disease patients with these cancers has also evolved. Novel strategies such as cancer genomic profiling now allow for better predictability of cancer recurrence and timing of transplant eligibility in candidates with PTM.30,39 Additionally, recent KDIGO (Kidney Disease Improving Global Outcomes) Clinical Practice Guidelines and the consensus expert opinion statements from the American Society of Transplantation recommend that patients with indolent and low-grade cancers should not be excluded as transplant candidates on the basis of untreated cancer alone.31,39,40 The consensus statements from the American Society of Transplantation also recommend that patients with certain early-stage cancers be considered treated and transplanted without a cancer-free wait time.31,40 Table 6 lists these cancers, including those whose SMR is not higher posttransplant (Figure 2) and those with high 5-y survival rates.31,39-42 TABLE 6.Malignant conditions that may proceed to transplantation without a cancer-free wait time or without treatmentCancerType/stage5-y Survival ratesPretransplant considerationsPosttransplant follow-up (test, frequency, who)Evidence/referenceProceed without treatment Prostatea≤Low risk orGleason ≤6>99% (≤3% risk of death/MetS during 15 y)Active surveillanceAST40 KDIGO39 ProstateLow-volumeintermediate riskGleason 7>99% (≤5% risk of death/MetS during 15 y)Depending on cancer characteristics, decision to proceed without treatment should be made jointly with urologists. Regardless of decision to treat. No wait timeActive surveillance or treatment per urologistAST40 Small renal masses≤1 cmActiveKDIGO39 Small renal masses≤4 cm95%–98%Depending on cancer characteristics, decisions to proceed without treatment should be made jointly with urologists. Regardless of decision to treat. No wait timeActive surveillance or consideration of surgeryAST40Gan et al41 Nonmelanoma skin cancerSuperficialActive surveillanceKDIGO39Proceed without a cancer-free wait time after potentially curative treatment Nonmetastatic prostate cancerGleason ≥720%–70% risk of MetS/death in 15 yDepending on nomogram-predicted cancer-specific deathActive SURVEILLANCEAST40 MelanomaIn situ99%Should have a wide local excisionFollow-up 3 mo post-KTAST31KDIGO39 BreastLow-riskDCISstage 197%–99%ER/PR negative may have slightly increased recurrence riskPer oncologist recommendationsKDIGO39AST40 ThyroidPapillary,follicular,medullary/stage I/<2 cm>99%Per oncologist recommendationsKDIGO39 CervicalSCC or adenoca/stage IA1/IA291%Per gynecologist recommendationsAST40ACS42 OvarianEpithelial/stage IA/IB/IC grade 1–292%–98%Per gynecologist recommendationsAST40ACS42 EndometrialStage IA/IB, grade 1–296%Per gynecologist recommendationsAST40ACS42 RCC≤T1b (>4 cm but ≤7 cm, FG 1–2), N0, M091%Per urologist recommendationsAST40 Bladder cancersIn situ97%Per urologist recommendationsKDIGO39ACS42ACS, American Cancer Society; AST, American Transplant Society; DCIS, ductal carcinoma in situ; ER, estrogen receptor; KDIGO, Kidney Disease Improving Global Outcomes; KT, kidney transplant; PR, progesterone receptor; RCC, renal cell carcinoma; SCC, squamous cell cancer. Malignant conditions that may proceed to transplantation without a cancer-free wait time or without treatment ACS, American Cancer Society; AST, American Transplant Society; DCIS, ductal carcinoma in situ; ER, estrogen receptor; KDIGO, Kidney Disease Improving Global Outcomes; KT, kidney transplant; PR, progesterone receptor; RCC, renal cell carcinoma; SCC, squamous cell cancer. Cancers that will need treatment before KT have previously been discussed in detail by Al-Adra et al and are not included in these tables.31,40 For the optimal approach and management to patients with plasma cell dyscrasias, the reader is kindly referred to a detailed article by Murakami et al.43 Because of the paucity of data in KT patients overall, and in the elderly KT cohort in particular, it is important to note that these expert opinions are severely limited, as they are extrapolated from cancer outcomes in the general population. In addition, as cancer therapies advance rapidly, overall patient survival and cancer-free survival will also improve. Therefore, these guidelines should be taken in the context of these limitations and nuances, and the ultimate decision must be made after a multidisciplinary discussion, considering the overall projected benefit of transplant, contextualized against the incompletely known risks of cancer recurrence, available contemporary therapies, and updated data on patient and cancer-free survival. Myth 7: Depleting Agents Should Never Be Used in Patients With Active Cancers or Cancers in Remission Depleting immunosuppressive agents, such as rabbit antithymocyte globulin (rATG), alemtuzumab, and rituximab, can be used in patients with active or PTM; however, their use warrants caution in patients already at risk of immune complications due to their biological age and immunosuppressive burden. Individual factors, such as cancer progression or recurrence risk, sensitization, donor compatibility, infectious risk, and planned maintenance regimens, must be carefully weighed into this decision. Depleting agents are associated with early posttransplant lymphoproliferative disorder. This risk appears more pronounced in younger recipients,44 likely influenced by their Epstein-Barr virus serologic status. Several studies link this association to rATG,45,46 whereas data regarding alemtuzumab remain conflicting. Notably, some studies report no increased risk of incident non–skin cancer malignancy with rATG compared with basiliximab in older recipients, potentially due to competing risks.47 Incomplete T-cell reconstitution after depleting agent use may contribute to long-term risk of cancer after KT. However, delineating the impact of depleting agents versus maintenance immunosuppression is difficult due to multiple limitations in retrospective and registry-based studies, and limited follow-up in clinical trials. Overall, total immunosuppressive load, along with the extent of depleting agent exposure, likely drives malignant risk in transplant recipients with cancer. Myth 8: All Patients With Historic or Current Cancers Should Be on Mammalian Target of Rapamycin Inhibitors Mammalian target of rapamycin (mTOR) inhibitors are one of the classic immunosuppressants in KT. De novo mTOR inhibitor use is associated with a higher risk of early posttransplant rejection compared with calcineurin inhibitor,48 yet mTOR inhibitor conversion in early posttransplant (6–12 mo) is associated with better estimated glomerular filtration rate, whereas the benefit is limited by higher metabolic complications such as posttransplant diabetes mellitus and lipid dysregulation, as well as higher risk of proteinuria. A randomized controlled trial (TUMORAPA study) demonstrated that sirolimus was effective in the secondary prevention of cutaneous squamous cell carcinoma in KT recipients, compared with cyclosporine,49 and exhibited sustained antitumoral response after 5 y of conversion.50 Despite this benefit, mTOR inhibitor use is not associated with a lower incidence of cancers other than nonmelanoma skin cancers.51 According to a meta-analysis, mTOR inhibitor conversion is associated with a higher risk of death, recognizing the limitations of the study and underlying data.52 Other dose-dependent side effects of mTOR inhibitors, including mucosal side effects, poor wound healing, edema, and anemia, can make their use more challenging. Taken together, not all patients will benefit from mTOR inhibitor conversion, and careful individualized risk-benefit assessment should be performed before conversion. Myth 9: Posttransplant Cancer Screenings are the Same as Cancer Screenings for the General Population Given the increased risk of cancer after KT, especially in the elderly, strategies to reduce cancer risk and identify cancer in early stages are critical. Cancer screening in KT recipients is based on recommendations for the general population due to limited data in the transplant population. The most common resource is the US Preventive Service Task Force cancer recommendations, which include graded evidence. Multiple transplant-related societies have published guidelines and recommendations that incorporate general population guidelines and transplant considerations, though these are not consistently updated. Table 7 reflects our cancer screening advice based on the most contemporary recommendations of US Preventive Service Task Force and/or transplant societies.53 TABLE 7.Recommendations for cancer screening in KT recipientsCancerAge, yScreeningFrequencySkin and lipAllSelf-examinationMonthlyAllExamination by a primary care physician or dermatologistAnnuallyCervical<65Pelvic examination and Pap SmearEvery 3 yColorectal45–74FOBTAnnuallySigmoidoscopyEvery 5 yColonoscopyEvery 10 yRenal cell carcinomaAllScreening in select populations can be consideredaUnclearProstateAllNot recommendedBreast40–74Mammography1–2 yPosttransplantation lymphoproliferative disordersONLY in seronegative recipients with seropositive donorAllPhysical examinationEvery 3 mo in the first year, then annuallyEBV viremia (ie, PCR)Monthly for the first 6 mo and then every 3 mo until the end of the first posttransplant yearHepatocellular carcinomaONLY for patients with liver disease, HBV, or HCV viremia before transplantAllAlpha-fetoprotein and abdominal ultrasoundEvery 6–12 moEvery 6–12 moLungIF 20+ PY smoking history AND actively smoking or quit within past 15 y50–80Low-dose chest CTAnnuallyAdapted from Cancer Screening and Cancer Treatment in Kidney Transplant Recipients53 with permission from the authors.CT, computed tomography; EBV, Epstein-Barr virus; FOBT, fecal occult blood test; HBV, hepatitis B virus; HCV, hepatitis C virus; KT, kidney transplant; Pap, Papanicolaou; PCR, polymerase chain reaction; PY, pack year; RCC, renal cell cancer.aCurrent RCC screening recommendations are highly variable and based on limited data. Risk stratified cancer screening can be considered for transplant recipients with acquired cystic kidney disease, long dialysis duration (>3 y), and hereditary RCC syndromes. Anyone with a history of RCC should undergo appropriate surveillance. Recommendations for cancer screening in KT recipients Adapted from Cancer Screening and Cancer Treatment in Kidney Transplant Recipients53 with permission from the authors. CT, computed tomography; EBV, Epstein-Barr virus; FOBT, fecal occult blood test; HBV, hepatitis B virus; HCV, hepatitis C virus; KT, kidney transplant; Pap, Papanicolaou; PCR, polymerase chain reaction; PY, pack year; RCC, renal cell cancer. aCurrent RCC screening recommendations are highly variable and based on limited data. Risk stratified cancer screening can be considered for transplant recipients with acquired cystic kidney disease, long dialysis duration (>3 y), and hereditary RCC syndromes. Anyone with a history of RCC should undergo appropriate surveillance. Cancer screening and resultant procedures have risks that can result in physical complications and mental/emotional consequences, including anxiety, depression, and suicidal ideation, and must be individualized in KT recipients, considering the patient’s overall health, life expectancy, and goals to avoid excess testing, overdiagnosis, and unnecessary treatment. Many elderly patients with multiple comorbidities and competing priorities (ie, other appointments, financial limitations, access to transportation) face challenges in maintaining intended cancer screening after transplant. Additionally, providers experience time limitations that can result in deferring preventative measures, including cancer screening. Building cancer screening into templated care plans can improve provider and patient engagement. Reviewing cancer screening risks, benefits, and patient-focused schedules on an annual basis ensures optimal outcomes. Myth 10: The Oncology Team Should Have the Final say on the Treatment Plan for Transplant Recipients Shared decision-making is key when caring for KT recipients with cancer. Patients with advanced kidney disease and cancer value shared information and transparency from clinicians. This becomes particularly evident for patients with posttransplant cancers who fear graft loss, which is one of the most concerning outcomes from a patient perspective.54 Building trusted relationships with patients, care partners, and multidisciplinary team of transplant nephrologists and oncologists is crucial. Although each discipline has distinctive expertise, with oncologists having knowledge related to cancer management and therapeutic options, transplant nephrologists should actively participate in the conversation to decide the best therapeutic options for patients that are in line with their goals and values. For KT recipients with cancer, having the perspectives of a multidisciplinary team to guide clinical care focused on patient priorities is crucial to arriving at patient-centered medical decisions. FUTURE DEVELOPMENT IN ONCONEPHROLOGY AND TRANSPLANTATION As oncology, onconephrology, and transplantation continue to advance rapidly, we anticipate a growing emphasis on personalized immune monitoring and targeted therapies that balance immunosuppression for graft survival against cancer risk. This includes genetic profiling and novel tumor markers to predict recurrence and survival, guide treatment decisions, and inform innovative approaches. Novel therapies, such as virus-specific T-cell therapy and chimeric antigen receptor therapy, will continue to evolve and become more common for transplant recipients with limited treatment options. As therapies become increasingly precise and individualized, care models will likely evolve toward dedicated onconephrology clinics and multidisciplinary teams that integrate cancer treatment, immunosuppression management, and graft preservation. Central to this approach will be patient-centered shared decision-making to navigate these complex therapeutic landscapes. Patient Viewpoint I learned of my renal disease at the age of 15 y. Since then, I have undergone 2 living-related renal transplants and 2 deceased donor renal transplants. Between transplants, I have used all forms of dialysis, including home nocturnal hemodialysis. I have also taken a variety of immunosuppressants, which continued post–graft failure and while on dialysis and awaiting the next transplant. Beginning in my late 20s, I have dealt with cancer: chronic vulvar intraepithelial neoplasia, breast cancer, and skin cancer. Despite these challenges, I have lived a full life. I attained higher education, advanced in my profession, traveled, and did all the things that people with good health often take for granted. Most importantly, I had more time to spend with my loved ones and to grow as a human. Transplantation, although not perfect, has allowed me to be a fully functioning person. Excellent care from my healthcare team, along with personal responsibility, has kept my cancer manageable. My transplant surgeon discussed the risks of another transplant and continued immunosuppression, considering my cancer history, among other challenges, with my family and me. The decision was easy. The alternative—dialysis, with no option for transplantation, was hopeless and frightening. Previously denied a transplant by another center due to my cancer history, my surgeon considered the entirety of my situation, including not just diagnoses in my medical chart, but also my current health and quality of life. His/our decision has given me the last healthy 8 y of my life free from dialysis or death from renal failure. Shared decision-making should be the standard, not a choice made in isolation by a physician or healthcare committee. An Oncologist’s Perspective Medical oncologists broadly encounter 2 scenarios when dealing with KT patients with cancer. First, a potential KT candidate with historic or current cancer. In this scenario, oncologists encounter the unfamiliar and uncomfortable terrain of considering the patient’s situation in the context of the broader KT waitlist and societal priority to optimize organ allocation. Routine cancer care is not a zero-sum game. One patient receiving cancer treatment does not prevent another from receiving it; KT is a different situation, and this can be uncomfortable for oncologists. To address this, it is important that oncologists clearly understand what is being asked of them by the KT teams. It is usually along the lines of clarifying the natural history of a prior cancer diagnosis including recurrence risk (most cancers have a variety of good risk calculators to help inform this), to comment on the extent to which immunosuppression re: KT could impact the natural history of the cancer, to clarify the types of therapy (and their impact to the allograft) and prognosis of the cancer should it recur, and the potential for development of secondary cancers. Second, KT recipients can develop a new cancer. For many patients, after a cancer diagnosis, their cancer care becomes the sun around which other medical care orbits. KT patients can present a somewhat different scenario, in that they are often medically savvy due to their preceding KT, on unique, specialized medications (eg, immunosuppressants, antimicrobials), and are frequently in close communication with a transplant nephrologist or primary nephrologist and doing regular laboratory testing. For most KT recipients, their primary focus since KT is on the optimum care and maintenance of their allograft function and health; a diagnosis of cancer destabilizes that focus, creating a potential for conflict of priorities (especially when using immunotherapy). KT patients have a longitudinal, trusting relationship with their kidney providers, and it is important that oncologists clearly communicate oncologic details to the KT and nephrology teams and proactively involve them in decision-making when appropriate. CONCLUSIONS Caring for a patient before and after KT has always been a team sport, involving many members from different professions and specialties—this approach becomes even more important in the case of older KT candidates and recipients with a history of, or current, malignant or premalignant conditions. Central to this multidisciplinary team is the patient, whose goals and values, guided by evidence-based outcomes and expert input, should drive the ultimate approach to care. Clear and honest communication between and among team members and with the patient and his/her family is of supreme importance. While making decisions with regard to transplanting older candidates with malignant and premalignant conditions, we should remember that the real comparison should not be between elderly transplant recipients with cancer history compared with other younger individuals with a cancer history, but rather a comparison of the risk/benefits of transplanting elderly candidates with cancer history to these same individuals remaining on dialysis. Using objective assessment tools and outcome prediction models geared toward older candidates and their comorbidities, while emphasizing shared decision-making among patients, their care partners, and healthcare providers, we can ensure that transplant decisions are made ethically and equitably in this vulnerable population. ACKNOWLEDGMENTS This article is a work product of the American Society of Transplantation’s Kidney Pancreas Community of Practice Frailty Workgroup. K.H. thanks the team at Northwestern Feinberg School of Medicine, Comprehensive Transplant Center, especially Dr John Friedewald, for her excellent transplant care. K.H. is receiving care at Northwestern University.